“`html
Vivoryon Therapeutics (Euronext: VVY) is set to announce its Q3 2025 financial performance on December 4, 2025. The report will include key operational updates. A webcast and conference call will be held at 3:00 pm CET / 9:00 am EST for investors and the public.
The live audio webcast will be accessible on the company’s investor relations site. Participants planning to dial in are encouraged to pre-register to expedite access. The company suggests calling in 15 minutes early to bypass potential delays.
Loading…
Loading translation…
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
Halle (Saale) / Munich, Germany – November 25, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a biopharmaceutical company focused on developing innovative therapies targeting inflammatory and fibrotic diseases, particularly in the kidney, will release its Q3 2025 financial results on Thursday, December 4, 2025. The announcement will be accompanied by an update on the company’s operational progress. Vivoryon will host a public conference call and live audio webcast to discuss the details.
Analysts anticipate close scrutiny of Vivoryon’s varoglutamstat program, a novel QPCT/L inhibitor currently under evaluation for diabetic kidney disease. Investors will be keen to learn about the latest clinical trial data, potential regulatory pathways, and projected timelines for market entry. Beyond the financials, the update is expected to shed light on Vivoryon’s strategic priorities and potential new indications for its drug pipeline.
Conference Call Details
Date: December 4, 2025
Time: 3:00 pm CET / 9:00 am EST
The conference call can be accessed via phone and webcast.
The live audio webcast will be available via Vivoryon´s website.
Those opting to join the conference call via phone are advised to pre-register to receive dedicated dial-in details, which will provide faster access to the call.
To ensure seamless access, participants are encouraged to dial in 15 minutes prior to the scheduled commencement of the call.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology firm specializing in the development of small molecule therapeutics for inflammatory and fibrotic kidney disorders. Emphasizing science and originality, the Company is dedicated to improving patient outcomes by modulating disease-relevant protein activity and stability. Vivoryon’s primary asset, varoglutamstat, is an oral QPCT/L inhibitor in development for diabetic kidney disease.
Forward-Looking Statements
This press release contains forward-looking statements relating to Vivoryon Therapeutics N.V.’s business strategy, future operations, market prospects, and product availability timelines. These statements are based on current management expectations and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update this information, except as required by law.
FAQ
When will Vivoryon (VVY) release Q3 2025 financial results?
Vivoryon will publish its Q3 2025 financial results on December 4, 2025.
What time is Vivoryon VVY’s Q3 2025 conference call and webcast?
The conference call and webcast are scheduled for 3:00 pm CET / 9:00 am EST on December 4, 2025.
How can investors access the Vivoryon (VVY) Q3 2025 webcast?
The live audio webcast will be available on Vivoryon’s investor website under Presentations & Webcasts.
How do I join Vivoryon VVY’s conference call by phone?
Pre-register via the provided registration page to receive dedicated dial-in details for the phone conference.
Will Vivoryon (VVY) discuss clinical and operational progress during the Q3 2025 call?
Yes; the company said it will provide an operational update alongside the Q3 2025 financial results during the call.
When should attendees dial in for the Vivoryon VVY Q3 2025 call to avoid delays?
Attendees are advised to dial in 15 minutes before the scheduled start time.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13550.html
